Other Events ·
At its 2026 Annual Meeting of Stockholders on June 11, 2026, Heron Therapeutics approved several key proposals
HRTXHeron Therapeutics, Inc.
At its 2026 Annual Meeting of Stockholders on June 11, 2026, Heron Therapeutics approved several key proposals. Stockholders authorized an increase of 16,560,000 shares for the 2007 Amended and Restated Equity Incentive Plan and an additional 10,000,000 shares for the 1997 Employee Stock Purchase Plan. The company also ratified the adoption of a Tax Benefits Preservation Plan on a nonbinding advisory basis. Additionally, stockholders elected seven directors, ratified the appointment of Withum Smith+Brown, PC as the independent auditor for fiscal year 2026, and approved executive compensation for 2025 on a nonbinding advisory basis. Heron Therapeutics is a biopharmaceutical company that develops and commercializes medicines for the treatment of pain and other medical conditions.